Effect of statins on serum apolipoprotein J and paraoxonase-1 levels in patients with ischemic heart disease undergoing coronary angiography

Angiology

Volumn 59, Issue 2, 2008, Pages 137-144

  Poulakou, Maria V ^a   Paraskevas, Kosmas I ^a,b   Vlachos, Ioannis S ^a   Karabina, Sonia Athena P ^c   Wilson, Mark R ^d   Iliopoulos, Dimitrios C ^a,e   Tsitsilonis, Serafim I ^a   Mikhailidis, Dimitri P ^b   Perrea, Despina N ^a,f  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITY OF WOLLONGONG   (Australia)

^e ATHENS MEDICAL CENTER   (Greece)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Apolipoprotein J; Ischemic heart disease; Paraoxonase 1; Statins

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CLUSTERIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; ENZYME ACTIVITY; EVALUATION; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PROTEIN BLOOD LEVEL; THERAPY EFFECT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT RESPONSE;

EID: 42049104453     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319707311722     Document Type: Article

References (44)

1. Ishikawa Y., Akasaka Y., Ishii T., et al. Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta. Arterioscler Thromb Vasc Biol. 1998 ; 18: 665-672.
2. Kujiraoka T., Hattori H., Miwa Y., et al. Serum apolipoprotein J in health, coronary heart disease and type 2 diabetes mellitus. J Atheroscler Thromb. 2006 ; 13: 314-322.
3. Trougakos IP, Poulakou M., Stathatos M., et al. Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp Gerontol. 2002 ; 37: 1175-1187.
4. Mackness MI, Abbott C., Arrol S., et al. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J. 1993 ; 294: 829-834.
5. Durrington PN, Mackness B., Mackness MI Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001 ; 21: 473-480.
6. Mackness MI, Arrol S., Abbott C., et al. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993 ; 104: 129-135.
7. Mackness B., Durrington P., McElduff P., et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003 ; 107: 2775-2779.
8. Sanghera DK, Aston CE, Saha N., et al. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet. 1998 ; 62: 36-44.
9. Sanghera DK, Saha N., Aston CE, et al. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol. 1997 ; 17: 1067-1073.
10. Ruiz J., Blanche H., James RW, et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 1995 ; 346: 869-872.
11. Heinecke JW, Lusis AJ Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis ? Am J Hum Genet. 1998 ; 62: 20-24.
12. Odawara M., Tachi Y., Yamashita K. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997 ; 82: 2257-2260.
13. Kerkeni M., Addad F., Chauffert M., et al. Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clin Biochem. 2006 ; 39: 821-825.
14. Wilson MR, Roeth PJ, Easterbrook-Smith SB Clusterin enhances the formation of insoluble immune complexes. Biochem Biophys Res Commun. 1991 ; 177: 985-990.
15. Abbott CA, Mackness MI, Kumar S., et al. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol. 1995 ; 15: 1812-1818.
16. Kujiraoka T., Oka T., Ishihara M., et al. A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. J Lipid Res. 2000 ; 41: 1358-1363.
17. Mackness MI, Harty D., Bhatnagar D., et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991 ; 86: 193-199.
18. Deakin S., Leviev I., Guernier S., et al. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol. 2003 ; 23: 2083-2089.
19. Ota K., Suehiro T., Arii K., et al. Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism. 2005 ; 54: 142-150.
20. Graner M., James RW, Kahri J., et al. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol. 2006 ; 47: 2429-2435.
21. Su SY, Chen JH, Huang JF, et al. Paraoxonase gene cluster variations associated with coronary heart disease in Chinese Han women. Chin Med J (Engl). 2005 ; 118: 1167-1174.
22. Mackness B., Hunt R., Durrington PN, et al. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997 ; 17: 1233-1238.
23. Savkovic V., Gantzer H., Reiser U., et al. Clusterin is protective in pancreatitis through anti-apoptotic and antiinflammatory properties. Biochem Biophys Res Commun. 2007 ; 356: 431-437.
24. Rastaldi MP, Candiano G., Musante L., et al. Glomerular clusterin is associated with PKC-alpha/beta regulation and good outcome of membranous glomerulonephritis in humans. Kidney Int. 2006 ; 70: 477-485.
25. Santilli G., Aronow BJ, Sala A. Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. J Biol Chem. 2003 ; 278: 38214-38219.
26. Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP Early statin therapy in patients with acute coronary syndrome. Hellenic J Cardiol. 2005 ; 46: 5-8.
27. Athyros VG, Mikhailidis DP, Papageorgiou AA,, et al. GREACE Collaborative Group. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin. 2004 ; 20: 627-637.
28. Chapman MJ The potential role of HDL- and LDLcholesterol modulation in atheromatous plaque development. Curr Med Res Opin. 2005 ; 21: S17-22.
29. Tsiara S., Elisaf M., Mikhailidis DP Early vascular benefits of statin therapy. Curr Med Res Opin. 2003 ; 19: 540-556.
30. van Leuven SI, Kastelein JJ Atorvastatin. Expert Opin Pharmacother. 2005 ; 6: 1191-1203.
31. Kanadasi M., Cayli M., Demirtas M., et al. The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol. Heart Vessels. 2006 ; 21: 291-297.
32. Mikhailidis DP, Wierzbicki AS HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. Curr Med Res Opin. 2000 ; 16: 139-146.
33. O'Connor PJ, Gray RJ, Maciosek MV, et al. Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings. Prev Chronic Dis. 2005 ; 2: A05.
34. Wierzbicki AS, Mikhailidis DP Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Int J Cardiol. 2002 ; 84: 53-57.
35. Ng DS The role of statins in oxidative stress and cardiovascular disease. Curr Drug Targets Cardiovasc Haematol Disord. 2005 ; 5: 165-175.
36. Marketou ME, Zacharis EA, Nikitovic D., et al. Early effects of simvastatin versus atorvastatin on oxidative stress and proinflammatory cytokines in hyperlipidemic subjects. Angiology. 2006 ; 57: 211-218.
37. Kural BV, Orem C., Uydu HA, et al. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia. Coron Artery Dis. 2004 ; 15: 277-283.
38. Paragh G., Torocsik D., Seres I., et al. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproeinaemia. Curr Med Res Opin. 2004 ; 20: 1321-1327.
39. Harangi M., Seres I., Varga Z., et al. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur J Clin Pharmacol. 2004 ; 60: 685-691.
40. Kassai A., Illyes L., Mirdamadi HZ, et al. The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin Biochem. 2007 ; 40: 1-5.
41. Aviram M., Rosenblat M. Paraoxonases and cardiovascular disease: pharmacological and nutritional influences. Curr Opin Lipidol. 2005 ; 16: 393-399.
42. Diamantopoulos EJ, Athyros VG, Yfanti GK,, et al. OLYMPIC Study Group. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) Study. Angiology. 2005 ; 56: 731-741.
43. Athyros VG, Elisaf M., Mikhailidis DP Undertreatment of dyslipidaemia in Greece. Atherosclerosis. 2004 ; 177: 215-216.
44. Barter P., Gotto AM, LaRosa JC,, et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007 ; 357: 1301-1310.